傳恆大中心全幢獲越秀地產(00123.HK)洽購近尾聲 或低於2015年購入價
據《星島日報》引述消息指,中國恆大(03333.HK)旗下灣仔「中國恆大中心」全幢獲越秀地產(00123.HK)洽購一事,已近尾聲,售價傳為105億元。
撿報越秀希望在港覓得全幢商廈自用,以配合業務發展。
外電上周引述消息稱,恆大提出了超過20億美元(約155.79億港元)的潛在價格。恆大於2015年11月以125億元向華人置業(00127.HK)購入灣仔美國萬通大廈全幢,物業樓高26層,總樓面約34.5萬平方呎,呎價約3.6萬元,當時創本港最大額商廈買賣及呎價最高紀錄,隨後改名並持有至今。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.